We all have our own microbiome, bacteria that live within our digestive system, in our lungs or on our skin. Most of our life, they help us maintain good health, but when things go wrong (poor diet, broad spectrum antibiotics), then our microbiome becomes unbalanced.
Scientists have linked such unbalance to diverse diseases such as diabetes, asthma and bipolar disorder. A healthy diet is a key part of maintaining good health. But when we’re already sick, the body needs help to 'reset' the microbiome.
To do this, our body makes natural compounds called defensins. Defensins regulate our microbiome and dampen immune reactions that can lead to poor wound healing, irritable bowel disease, Crohn’s & Ulcerative Colitis.
The microbiota is the microflora that resides on all bodily surfaces - on the skin, in the lungs, in the saliva and oral mucosa and in the gastrointestinal tract.
The microbiota includes bacteria, fungi, viruses and archaeae. Many of these microorganisms undertake tasks that are useful for the human host e.g. as part of metabolism and assist in maintaining processes necessary for a healthy body.
The majority of microorganisms in the human microbiota are however inadequately investigated and the interplay with the human host is not fully understood.
New research indicates that dysregulation of the human microbiota might be associated with a variety of human diseases such as obesity, inflammatory bowel disease, Crohns disease, skin and eye conditions and even cancer.
Defensin Therapeutics ApS
COBIS, Ole Maaloesvej 3
DK-2200 Copenhagen N
+45 25 47 16 46
Defensin Therapeutics has generated preclinical data with both oral, intranasal and subcutaneous administration of two different defensins - human beta defensin-2 (hBD-2) and Human Defensin 5 (HD5), in animal models of both IBD, asthma and metabolic syndrome.
IBD. Efficacy, measured as disease activity index, on par with standard IBD treatments like anti TNF-α, cyclosporine and prednisolone but without any side effects, has been demonstrated in the three major IBD animal models - CD4+CD25+ T-cell transfer, DSS and TNBS with hBD-2.
Asthma. Efficacy, measured as airway hyper responsiveness and dynamics, superior to the standard treatment with dexamethasone but without any side effects, with complete normalization of asthma cytokines has been demonstrated both prophylactically and therapeutically in models of acute asthma with hBD-2.
Metabolic syndrome. Efficacy, measured as fasting insulin, insulin tolerance, glucose tolerance, insulin resistance index, weight gain, fat %, has been demonstrated both prophylactically and as therapeutic intervention in an animal high fat diet model of metabolic syndrome with both HD5 and hBD-2.